Cellulose

[{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evonik Company JenaCell Launches Wound Dressing Epicite\u00ae Balance for Chronic Wounds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cellulose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ JeNaCell"},{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evonik Company JeNaCell Launches Wound Dressing Epicite\u00ae Balance for Chronic Wounds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cellulose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ JeNaCell"}]

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 2 USDMF, 2 VMF, 1 Listed Suppliers

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Evonik

Germany

CPhI Worldwide, Milan

Booth #5B41

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Cellulose

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Approved

Sponsor : JeNaCell

Deal Size : Not Applicable

Deal Type : Not Applicable

DEALS_DEV

Evonik Company JenaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds

Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.

Brand Name : Epicite® Balance

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 14, 2023

Lead Product(s) : Cellulose

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Sponsor : JeNaCell

Deal Size : Not Applicable

Deal Type : Not Applicable